Giao dịch Dyadic International, Inc. - DYAI
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. It offers DYAI-100, SARS-CoV-2-S-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to validate to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; and research collaborations with Jiangsu Hengrui Medicine, Serum Institute of India Pvt., Ltd., and WuXi Biologics. It also has a collaboration with TurtleTree Scientific Pte. Ltd. to develop various recombinant protein growth factors; and a partnership agreement with Medytox, Inc. and Syngene International Limited to develop COVID-19 vaccines and/or boosters. The company was founded in 1979 and is headquartered in Jupiter, Florida. Bài viết chia sẻ mới nhất

Dự báo giá vàng năm 2026: Các mức giá mục tiêu từ bên thứ baVàng giao ngay (XAU) được giao dịch ở mức $4,582.82 vào lúc 9:44 UTC ngày 27 tháng 8 năm 2026, sau khi lạm phát PCE lõi tháng 7 tăng 3.3% so với cùng kỳ năm trước. Tìm hiểu dự báo giá vàng hôm nay, dự báo giá vàng mới nhất từ bên thứ ba và phân tích kỹ thuật.
15:39, 2 tháng 10 2026